Ali Ardakani is a visionary biotech executive, entrepreneur, and corporate strategist with over 20 years of leadership experience across the life sciences sector. His career spans innovation in oncology, ophthalmology, immunology and medical devices, guiding projects from early research through to FDA approvals and global commercialization.
Ali is the Founder & Managing Director of Novateur Ventures, where he partners with companies worldwide to accelerate life science breakthroughs. He is also the Co-Founder & CEO of Optigo Biotherapeutics, an ophthalmology R&D company advancing novel therapies. Previously, he served as Senior Vice President of Device and Business Development at Beyond Air (NASDAQ: XAIR), where he played a pivotal role from early-stage development to public offering and global expansion.
A passionate advocate for the life sciences community, Ali serves as a Director on the Board of the BC Cancer Foundation, as well as a Director on the Board of Life Sciences British Columbia. He is also an Associate at Creative Destruction Lab. Ali’s continued involvement across these organizations reflects his deep dedication to advancing innovation, impact, and hope for patients and families across British Columbia and beyond.
Throughout his career, Ali has contributed to the success of multiple mergers and acquisitions, licensing deals, and financing rounds, and remains committed to building collaborations that transform patient care. Ali's leadership and commitment to the sector have been recognized through prestigious honours, including the Milton Wong Community Leadership Award at the 2025 LSBC Annual Awards and being named a 2025 Business in Vancouver Top 500 Leader, in the Innovation category.
